Phase 2 N=69 Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Neoplasm, Gastric
Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=363 A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — -0.41; -0.71; -0.69; -0.76 Percent — p=<0.001
Phase 2 N=13 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Breast Cancer · Ovarian Cancer · Endometrial Cancer
Primary: Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. — 0; 0; 1; 2 Participants
Phase 2 N=80 Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in 24-hour Weighted Mean Plasma Glucose — -34.9; -28.6; -9.0 mg/dL — p=<0.001
Phase 2 N=24 A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
Osteoporosis
Primary: Plasma C-terminal Telopeptide of Type I Collagen (CTx-1)(% Change From Baseline) — -74.17; -71.99; -68.40 % Change in Baseline CTx-1
Phase 2 N=44 Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Hepatitis C Virus Infection
Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale
Phase 2 N=43 Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain
Pain
Primary: Acetylcholine Concentration in Cerebrospinal Fluid — 406; 383 picograms per milliliter (pg/ml)
Phase 2 N=218 A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
Migraine
Primary: Change From Baseline in Mean Migraine Headache Rates During the Entire 14-week Maintenance Period — -1.4; -1.4; -1.6 Number of migraine headaches
Phase 2 N=55 Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Complete Response = Morphologic Complete Remission (mCR) — 13 Participants
Phase 2 N=21 Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Number of Patients With Natural Killer (NK) Cell Expansion — 2 Participants
Phase 2 N=163 A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
Obesity
Primary: Change in Body Weight — 109.48; 107.64; -5.06; -1.61 kg — p=<0.0001
Phase 2 N=41 Stem Cell Transplantation for Hurler
Mucopolysaccharidosis I · Mucopolysaccharidosis VI · Mannosidosis
Primary: Mean Percentage of Donor Cells in Study Population (Chimerism). — 85.8; 73.2; 84.6; 81.1 Percentage
Phase 2 N=44 Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms
Restless Legs Syndrome
Primary: Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo — 2.6; 2.2; 2.5; 2.0 score on a scale
Phase 2 N=60 Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Clinical Benefit Response (CBR) According to RECIST — 15; 17; 32 participants
Phase 2 N=99 A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
Myelodysplastic Syndrome
Primary: Number of Participants Who Achieved Overall Response — 33 participants